Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HC-7366 with Immunotherapy in Kidney Cancer
NCT07401875Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HC-7366 in clear cell renal cell carcinoma (ccRCC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events at 1 year, Overall Response Rate and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
HC-7366
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07401875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401875.